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pidermolysis bullosa acquisita (EBA) is an
autoimmune mucocutaneous blistering dis-
ease.1,2 Cutaneous involvement presents with
blisters primarily on trauma-prone areas healing with
milia.1,2 Mucosal involvement can lead to irreversible
scarring. The treatment of EBA is based on anecdotal
reports in the literature with systemic therapies.3-7
Mycophenolate mofetil (MMF) is an immune-
suppressing agent that has been reported to be
effective in the treatment of autoimmune mucocuta-
neous blistering diseases.3,4,8-11 This report describes
the successful treatment of 4 patients with EBA using
MMF as a steroid-sparing agent at our center along
with a long term follow-up.
CASE SERIES
This retrospective study consisted of 4 patients
with EBA treated with MMF, and was conducted with
the approval of the institutional review board of the
University of Alabama at Birmingham. The diagnosis
was confirmed in all 4 patients with a skin biopsy
specimen, immunopathology, and serology.1,2 Skin
biopsy specimens demonstrated a subepidermal
split with a mixed inflammatory infiltrate on routine
histology, and IgG binding along the basement
membrane zone on direct immunofluorescence.
Serological studies with indirect immunofluores-
cence demonstrated antibasement membrane zone
antibodies usingmonkey esophagus as substrate and
autoantibody binding to the dermal side of the salt-
split skin. The response to MMF treatment was
assessed based on the following criteria: (1) healing
of involvement of the initial presentation; and (2)
absence of new lesions. Complete control wasthe Department of Dermatology, University of Alabama at
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bmc.edu.defined as patients meeting both response criteria 1
and 2 and discontinuing systemic corticosteroids.
Partial control was defined as patients meeting only
criteria 1 and being unable to discontinue steroids.
Two patients were male and 2 were female. The
age at onset ranged from 48 to 86 (mean 61) years.
All patients had both mucosal and cutaneous
involvement. The most common areas of mucosal
involvement included oral (4), nasal (4), pharyngeal
(2), and laryngeal (1). The patient with laryngeal
involvement required a tracheostomy. Cutaneous
involvement was present on the extremities and acral
surfaces and amount of body surface area involve-
ment is presented in Table I.
All patients were initially treated with prednisone
with dosages ranging between 40 and 60 mg/d.
Steroid-sparing agents before MMF included the
following with their dosages: azathioprine (100-
200 mg/d), dapsone (100-200 mg/d), colchicine
(0.6-1.2mg/d), and tetracycline (2 g/d). The duration
of systemic treatments before starting MMF ranged
between 16 and 26 (mean 22) months. All 4 patients
received MMF with a dosage ranging between 2 and
3 g/d. An effective response to MMF was observed
after 4 to 12 (mean 7) months and the dosage of
prednisone was gradually reduced. Three patients
achieved complete control and 1 patient had partial
control because he was unable to taper below
10mg/d of prednisone. However, this was the lowest
dosage he was able to achieve after failing to
respond to previous treatments. The details of each
patient are presented in Table I. Local supportive
care was also recommended including avoiding
trauma and infection, and the use of the followingJAAD Case Reports 2015;1:321-3.
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Table I. Clinical features, prior treatments, and mycophenolate mofetil treatment of epidermolysis bullosa
acquisita
Age at onset,
y/gender
Clinical features
(mucosal/cutaneous BSA)
Prior treatments
to MMF
Duration of prior
treatments, mo
MMF (maximum)
dosage for control, g/d Response
48/F Oral, nasal, pharyngeal,
laryngeal
20% BSA
Prednisone (40 mg/d) N/A 2 Complete control
53/F Oral, nasal, pharyngeal
20% BSA
Prednisone (40 mg/d)
Dapsone (100 mg/d)
Azathioprine (100 mg/d)
16 3 Complete control
56/M Oral, nasal
20% BSA
Prednisone (60 mg/d)
Tetracycline (2 g/d)
Dapsone (200 mg/d)
Colchicine (1.2 mg/d)
Azathioprine (200 mg/d)
24 3 Partial control
86/M Oral, nasal
30% BSA
Prednisone (60 mg/d)
Dapsone (100 mg/d)
Colchicine (1.2 mg/d)
26 2 Complete control
BSA, Body surface area involved (cutaneous); F, female; M, male; MMF, mycophenolate mofetil; N/A, MMF was started with prednisone.
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facilitate healing: triamcinolone 0.1%, betametha-
sone diproprionate 0.05%, and halobetasol propio-
nate 0.05%. After a mean follow-up period of 9 years
(range 4-12 years) only 1 of the 4 patients was able to
discontinue MMF.
DISCUSSION
MMF is an immune-suppressing agent that has
been used in the treatment of autoimmune mucocu-
taneous blistering disease.3,4 However, there are very
few case reports that have described its use in EBA.8-11
This study described 4 patients who were
successfully treated with MMF for extensive involve-
ment with EBA. MMF was instituted as a steroid-
sparing agent after failure of response was observed
to multiple conventional treatments. Three of the 4
patients were able to completely discontinue sys-
temic corticosteroids and establish complete control
of their disease with just MMF as monotherapy.
This included 1 patient with laryngeal involvement
requiring a tracheostomy who is currently only
taking MMF at 500 mg/d as monotherapy while
maintaining complete control. She has also under-
went successful removal of her T-tube and repair of
the open anterior tracheal wall with no further issues
with breathing or swallowing and her voice has
remained stable.
Although the precisemechanism of action of MMF
in EBA is unclear, MMF is an immune suppressant
that has been shown to inhibit the proliferation of B
and T lymphocytes.4 This could lead to a decrease in
the production of autoantibodies, specifically to
collagen VII, resulting in clinical control of the
disease.MMF has been reported to have multiple side
effects including gastrointestinal, genitourinary, in-
fectious, and neurologic.3 Two of our patients
reported gastrointestinal side effects when they
were taking dosages greater than 2.5 g/d and
resolved in both patients when the dosage was
reduced to 2 g/d.
Because EBA is a chronic disease, the length of
therapy can vary widely. We have been unsuccessful
in discontinuing MMF as monotherapy in 2 of the 3
patients in the complete control group. An attempt to
slowly taper the MMF in 1 patient when she had been
stable at 2 g/d for 2 years resulted in an exacerbation
with nasal involvement and localized scarring after
reaching a dosage of 500 mg/d. Complete control of
the disease was re-established in this patient by
increasing the dosage of MMF to 2 g/d. Hence, MMF
may be necessary as long-term maintenance treat-
ment in some patients.
There are several limitations to this study including
a very small cohort of patients and lack of a control
group. The use of MMF is also limited by the higher
cost of the medication compared with other oral
conventional alternative agents. Because treatment
choices are limited, MMF could still be a viable
alternative for patients with EBA who have contrain-
dications to or failed other systemic therapies. Larger
multicenter randomized controlled trials are needed
to evaluate the efficacy and role of MMF for the
treatment of EBA.
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